No image available for this title

LITERATURE

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections


The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials.
Intravenous meropenem/vaborbactam (Vabomere™) is the frst carbapenem/β-lactamase inhibitor combination approved in the
USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis. Vaborbactam is a potent
inhibitor of class A serine carbapenemases, which, when combined with the antibacterial meropenem, restores the activity of
meropenem against β-lactamase producing Enterobacteriaceae, particularly Klebsiella pneumoniae carbapenemase (KPC)-
producing Enterobacteriaceae. Meropenem/vaborbactam demonstrated excellent in vitro activity against Gram-negative clinical
isolates, including KPC- and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. In the phase 3, noninferiority TANGO I trial in patients with cUTIs, intravenous meropenem/vaborbactam was noninferior to intravenous piperacillin/
tazobactam for overall success (composite of clinical cure and microbial eradication; FDA primary endpoint) and microbial
eradication (EMA primary endpoint)


Availability

Tripenem-007Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Drugs (2018) 78:1259–1270
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous